Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are highly heterogeneous myeloid diseases, characterized by frequent genetic/chromosomal aberrations. Olaparib is a potent, orally bioavailable poly(ADP-ribose) polymerase 1 (PARP1) inhibitor with acceptable toxicity profile, designed as targeted therapy for DNA repai...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraoni, Isabella, Consalvo, Maria Irno, Aloisio, Francesca, Fabiani, Emiliano, Giansanti, Manuela, Di Cristino, Francesca, Falconi, Giulia, Tentori, Lucio, Di Veroli, Ambra, Curzi, Paola, Maurillo, Luca, Niscola, Pasquale, Lo-Coco, Francesco, Graziani, Grazia, Voso, Maria Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769925/
https://www.ncbi.nlm.nih.gov/pubmed/31527467
http://dx.doi.org/10.3390/cancers11091373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769925/
https://www.ncbi.nlm.nih.gov/pubmed/31527467
http://dx.doi.org/10.3390/cancers11091373

Ejemplares similares